Disparities Seen in Treatment of Middle Ear Infections in US Children
Socially disadvantaged children less likely to receive treatment for recurrent or suppurative otitis media
Otic Disorders
Pedmark Now Available to Reduce Risk of Cisplatin-Induced Hearing Loss in Children
Pedmark is the first FDA-approved therapy indicated to reduce the risk of cisplatin-induced hearing loss in children.
MPR Weekly Dose Podcast #132
Warning about a new social media challenge; treatment approvals in cisplatin-associated ototoxicity, cerebral adrenoleukodystrophy, MRI contrasting and a generic version of Tazorac.
Pedmark Approved for Pediatric Cisplatin-Associated Ototoxicity
The approval was based on data from 2 pivotal phase 3 trials, which evaluated Pedmark in pediatric patients undergoing treatment with cisplatin-based chemotherapy.
FDA Issues Final Rule for Over-the-Counter Hearing Aids
The final rule takes effect in 60 days and consumers will be able to purchase hearing aids directly from stores or online retailers as soon as mid-October.
Link Between Analgesics, Incident Tinnitus Explored in Women
No increased risk for tinnitus seen with low-dose aspirin, but increase seen with moderate-dose aspirin for those younger than 60 years, NSAIDS, acetaminophen
FDA Rejects Pedmark NDA Again Citing Manufacturing Deficiencies
The application could not be approved in its present form due to manufacturing deficiencies.
FDA Eases Access to Cheaper Over-the-Counter Hearing Aids
Proposal would create a category of hearing aids that could be sold directly to consumers, without medical exam or audiologist fitting
Watchful Waiting for Acute Otitis Media Often Not Followed in Primary, Acute Care Settings
Study findings did show high adherence to guidelines with respect to medication use.
Cisplatin-Induced Hearing Loss Up for Young Children With Cancer
Cumulative incidence highest in patients aged 5 years and younger; factors that influence development include cumulative dose of cisplatin
